SIGLEC6

Summary

SIGLEC6 (sialic acid binding Ig like lectin 6, HGNC:10875) is a protein-coding gene on chromosome 19q13.41, encoding Sialic acid-binding Ig-like lectin 6 (O43699). Putative adhesion molecule that mediates sialic-acid dependent binding to cells.

This gene encodes a member of the SIGLEC (sialic acid binding immunoglobulin-like lectin) family of proteins. The encoded transmembrane receptor binds sialyl-TN glycans and leptin. Placental expression of the encoded protein is upregulated in preeclampsia.

Source: NCBI Gene 946 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 76 total
• MANE Select transcript: NM_001245

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10875
Approved symbol	SIGLEC6
Name	sialic acid binding Ig like lectin 6
Location	19q13.41
Locus type	gene with protein product
Status	Approved
Aliases	OB-BP1, SIGLEC-6, CD327
Ensembl gene	ENSG00000105492
Ensembl biotype	protein_coding
OMIM	604405
Entrez	946

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000343300, ENST00000346477, ENST00000359982, ENST00000391797, ENST00000425629, ENST00000436458, ENST00000474054, ENST00000489837, ENST00000496422

RefSeq mRNA: 6 — MANE Select: NM_001245 NM_001177547, NM_001177548, NM_001177549, NM_001245, NM_198845, NM_198846

CCDS: CCDS12834, CCDS12835, CCDS12836, CCDS54307, CCDS54308, CCDS59417

Canonical transcript exons

ENST00000425629 — 8 exons

Exon	Start	End
ENSE00000723576	51529724	51529981
ENSE00003210708	51517819	51520255
ENSE00003492149	51527747	51527828
ENSE00003542454	51531160	51531519
ENSE00003580663	51528160	51528253
ENSE00003584502	51530681	51530959
ENSE00003633624	51530437	51530484
ENSE00003842657	51531582	51531670

Expression profiles

Bgee: expression breadth ubiquitous, 131 present calls, max score 89.95.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 6.7083 / max 1399.1258, expressed in 172 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182453	3.4001	126
182451	1.4479	68
182456	0.9455	56
182454	0.7250	46
182455	0.1751	26
182443	0.0147	7

Top tissues by expression

263 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	89.95	silver quality
placenta	UBERON:0001987	89.05	gold quality
tibialis anterior	UBERON:0001385	75.70	silver quality
rectum	UBERON:0001052	75.00	gold quality
pancreatic ductal cell	CL:0002079	73.42	gold quality
gall bladder	UBERON:0002110	73.21	gold quality
ileal mucosa	UBERON:0000331	71.19	gold quality
lymph node	UBERON:0000029	70.74	gold quality
vermiform appendix	UBERON:0001154	69.26	gold quality
small intestine Peyer’s patch	UBERON:0003454	68.26	gold quality
caecum	UBERON:0001153	68.25	gold quality
epithelial cell of pancreas	CL:0000083	68.24	silver quality
small intestine	UBERON:0002108	67.49	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.14	gold quality
lower esophagus	UBERON:0013473	67.10	gold quality
smooth muscle tissue	UBERON:0001135	66.19	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.13	gold quality
upper lobe of left lung	UBERON:0008952	65.81	gold quality
upper lobe of lung	UBERON:0008948	65.50	gold quality
cervix squamous epithelium	UBERON:0006922	64.22	gold quality
mucosa of stomach	UBERON:0001199	63.62	gold quality
colonic epithelium	UBERON:0000397	63.53	silver quality
lung	UBERON:0002048	63.38	gold quality
fundus of stomach	UBERON:0001160	63.20	gold quality
mucosa of urinary bladder	UBERON:0001259	62.75	gold quality
esophagus	UBERON:0001043	62.73	gold quality
right coronary artery	UBERON:0001625	62.49	gold quality
deltoid	UBERON:0001476	62.38	silver quality
granulocyte	CL:0000094	62.18	gold quality
lower lobe of lung	UBERON:0008949	62.16	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	21.40
E-CURD-122	yes	11.58
E-MTAB-8410	yes	10.75
E-GEOD-130148	yes	9.24
E-MTAB-9801	yes	6.53
E-MTAB-5061	yes	4.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

35 targeting SIGLEC6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-7156-5P	99.64	68.81	1369
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-5007-3P	99.51	68.14	1242
HSA-MIR-216A-5P	99.50	68.02	1288
HSA-MIR-4273	99.45	67.93	1206
HSA-MIR-148A-5P	99.30	68.27	1141
HSA-MIR-4520-2-3P	99.14	69.28	1009
HSA-MIR-323B-3P	99.14	68.89	725
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-4711-3P	98.97	66.87	1020
HSA-MIR-4520-3P	98.75	66.55	963
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-4277	98.34	67.17	1323
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-4769-3P	97.95	68.17	1002
HSA-MIR-6817-5P	97.95	67.86	1026
HSA-MIR-6515-5P	97.08	65.48	1219
HSA-MIR-346	97.01	66.97	662
HSA-MIR-664B-5P	96.74	67.50	509
HSA-MIR-642B-5P	96.37	67.26	745

Literature-anchored findings (GeneRIF, showing 13)

• the negative signaling potential of Siglec-6 may have a role in human-specific placental expression, to slow the tempo of the human birth process (PMID:17580316)
• Preeclampsia involves changes in the gene expression of SIGLEC6 in placental cytotrophoblasts. (PMID:18818296)
• GdA interacts with Siglec-6 to suppress trophoblast invasiveness by down-regulating the ERK/c-Jun signaling pathway. (PMID:21880722)
• Siglec6 and leptin play a role in the aberrant properties characteristic of gestational trophoblastic disease, namely excess proliferation and invasion. (PMID:23089140)
• Siglec-6 expression is increased in preterm preeclampsia placentas. (PMID:23171684)
• Study findings illustrate that SIGLEC6 is a functionally inhibitory receptor on mast cells and suggest that SIGLEC6 expression may be relevant for mast cells activity in the tumor microenvironment of colorectal cancer. (PMID:30294327)
• Glycosylated Siglec-6 expression in syncytiotrophoblast-derived extracellular vesicles from preeclampsia placentas. (PMID:32998819)
• Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. (PMID:34147404)
• Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells. (PMID:35406705)
• Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils. (PMID:35953001)
• Elevated trophoblastic Siglec6 contributes to the impairment of vascular endothelial cell functions by downregulating Wnt6/beta-catenin signaling in preeclampsia. (PMID:36113626)
• Siglec-6 Signaling Uses Src Kinase Tyrosine Phosphorylation and SHP-2 Recruitment. (PMID:36359823)
• Siglec-6 mediates the uptake of extracellular vesicles through a noncanonical glycolipid binding pocket. (PMID:37087495)

Cross-species orthologs

0 orthologs

Paralogs (16): CD22 (ENSG00000012124), SIGLEC1 (ENSG00000088827), SIGLEC8 (ENSG00000105366), CD33 (ENSG00000105383), MAG (ENSG00000105695), SIGLEC9 (ENSG00000129450), SIGLEC10 (ENSG00000142512), TMEM25 (ENSG00000149582), SIGLEC11 (ENSG00000161640), SIGLEC16 (ENSG00000161643), SIGLEC7 (ENSG00000168995), SIGLECL1 (ENSG00000179213), SIGLEC15 (ENSG00000197046), SIGLEC14 (ENSG00000254415), SIGLEC12 (ENSG00000254521), SIGLEC5 (ENSG00000268500)

Protein

Protein identifiers

Sialic acid-binding Ig-like lectin 6 — O43699 (reviewed: O43699)

Alternative names: CD33 antigen-like 1, CDw327, Obesity-binding protein 1

All UniProt accessions (1): O43699

UniProt curated annotations — full annotation on UniProt →

Function. Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.

Subunit / interactions. Interacts with LEP.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Expressed at high levels in placenta (cyto- and syncytiotrophoblastic cells) and at lower levels in spleen, peripheral blood leukocytes (predominantly B-cells) and small intestine.

Domain organisation. Contains 1 copy of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.

Miscellaneous. Should not be confused with SIGLEC5 which has been called CD33L2.

Similarity. Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family.

Isoforms (6)

UniProt ID	Names	Canonical?
O43699-1	1, Membrane-bound, CD33L1	yes
O43699-2	2, Secreted, CD33L2
O43699-3	3
O43699-4	4
O43699-5	5
O43699-6	6

RefSeq proteins (6): NP_001171018, NP_001171019, NP_001171020, NP_001236, NP_942142, NP_942143 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003006	Ig/MHC_CS	Conserved_site
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013106	Ig_V-set	Domain
IPR013151	Immunoglobulin_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR051036	SIGLEC	Family

Pfam: PF00047, PF07679, PF07686

UniProt features (36 total): sequence conflict 8, splice variant 7, glycosylation site 4, disulfide bond 4, domain 3, topological domain 2, sequence variant 2, short sequence motif 2, signal peptide 1, chain 1, binding site 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43699-F1	77.55	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 122

Disulfide bonds (4): 46–172, 51–104, 166–215, 274–319

Glycosylation sites (4): 103, 149, 163, 233

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 77 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_CELL_CELL_SIGNALING, BROWNE_HCMV_INFECTION_48HR_DN, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP, GOMF_ORGANIC_ACID_BINDING, WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP, GOMF_SIALIC_ACID_BINDING, KRAS.DF.V1_DN, CHAF1B_TARGET_GENES, NFKBIA_TARGET_GENES, ZFP91_TARGET_GENES, ZNF766_TARGET_GENES, ZNF768_TARGET_GENES, MIR670_3P, GSE10856_CTRL_VS_TNFRSF6B_IN_MACROPHAGE_DN

GO Biological Process (2): cell adhesion (GO:0007155), cell-cell signaling (GO:0007267)

GO Molecular Function (3): carbohydrate binding (GO:0030246), sialic acid binding (GO:0033691), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Adaptive Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
binding	2
cellular process	1
cell communication	1
signaling	1
carboxylic acid binding	1
carbohydrate derivative binding	1
cytoplasm	1
membrane	1
cell periphery	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1014 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SIGLEC6	LEP	P41159	931
SIGLEC6	AXL	P30530	575
SIGLEC6	SLAMF1	Q13291	567
SIGLEC6	SIGLEC15	Q6ZMC9	543
SIGLEC6	FCRL4	Q96PJ5	509
SIGLEC6	ST6GAL1	P15907	492
SIGLEC6	PAPPA2	Q9BXP8	483
SIGLEC6	CLEC9A	Q6UXN8	482
SIGLEC6	MPPE1	Q53F39	480
SIGLEC6	CLEC4C	Q8WTT0	479
SIGLEC6	IL3RA	P26951	474
SIGLEC6	CD1C	P29017	450
SIGLEC6	THBD	P07204	430
SIGLEC6	IL33	O95760	425
SIGLEC6	AWAT2	Q6E213	420

IntAct

24 interactions, top by confidence:

A	B	Type	Score
SIGLEC6	TCF4	psi-mi:“MI:0915”(physical association)	0.560
FHL2	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.560
	SIGLEC6	psi-mi:“MI:0407”(direct interaction)	0.440
LEP	SIGLEC6	psi-mi:“MI:0407”(direct interaction)	0.440
BTNL8	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
CD300LB	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
FCAR	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
SIGLEC6	FSTL5	psi-mi:“MI:0915”(physical association)	0.400
IL23A	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
KIR2DS4	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
LRIT1	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
MOG	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
SIGLEC6	MPZ	psi-mi:“MI:0915”(physical association)	0.400
PILRA	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.400
ECE1	SIGLEC6	psi-mi:“MI:0915”(physical association)	0.370
SIGLEC6	rfbD	psi-mi:“MI:0915”(physical association)	0.000
SIGLEC6		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (7): FHL2 (Two-hybrid), TCF4 (Two-hybrid), LGALS3BP (Reconstituted Complex), SIGLEC6 (Proximity Label-MS), SIGLEC6 (Two-hybrid), MALL (Two-hybrid), ZNF655 (Two-hybrid)

ESM2 similar proteins: A0A0K2S4Q6, A2A7V7, A6NI73, A8K4G0, O43699, O75019, O75022, O75023, O75871, O76036, P0C191, P20138, P24071, P40198, P59901, P80943, Q08708, Q13410, Q28110, Q3U497, Q496F6, Q64JA4, Q6GTX8, Q6ISS4, Q6PI73, Q6UXZ3, Q7TSN2, Q863H2, Q8C567, Q8K249, Q8MJZ2, Q8MJZ7, Q8N149, Q8N423, Q8N6C8, Q8NHJ6, Q8NHL6, Q8VBT3, Q8VCH2, Q95JB9

Diamond homologs: A6NMB1, D3YXG0, O15389, O43699, O60469, P20138, P35329, Q08ET2, Q63994, Q64JA4, Q80ZE3, Q8N441, Q8VHZ8, Q91Y57, Q920G3, Q95LH0, Q96LC7, Q96PQ1, Q96RL6, Q96RW7, Q9ERC8, Q9NYZ4, Q9Y286, Q9Y336, Q460M5, Q6ZMC9, Q80TG9, Q8N7X8, Q9BE71, Q9ULH4, A1KZ92, A2AJ76, A2ASS6, P98160, Q28173, Q62151, Q63495, Q8BQC3, Q8NDA2, Q9QZS7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	67
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1477 predictions. Top by Δscore:

Variant	Effect	Δscore
19:51530679:A:AC	donor_gain	1.0000
19:51530680:C:CC	donor_gain	1.0000
19:51520255:CCT:C	acceptor_gain	0.9900
19:51529742:G:C	donor_gain	0.9900
19:51530675:ACTC:A	donor_loss	0.9900
19:51530676:CTCA:C	donor_loss	0.9900
19:51530677:TCA:T	donor_loss	0.9900
19:51530678:CA:C	donor_loss	0.9900
19:51530679:A:T	donor_loss	0.9900
19:51530680:CAG:C	donor_gain	0.9900
19:51531191:A:AC	donor_gain	0.9900
19:51531217:TCA:T	donor_gain	0.9900
19:51529723:CAATG:C	donor_gain	0.9800
19:51529741:A:AC	donor_gain	0.9800
19:51529810:A:AC	donor_gain	0.9800
19:51529811:C:CC	donor_gain	0.9800
19:51529984:T:C	acceptor_gain	0.9800
19:51529984:T:TC	acceptor_gain	0.9800
19:51530672:AGCAC:A	donor_loss	0.9800
19:51530673:GCACT:G	donor_loss	0.9800
19:51530674:CACTC:C	donor_loss	0.9800
19:51530680:CA:C	donor_gain	0.9800
19:51530680:CAGG:C	donor_gain	0.9800
19:51530680:CAGGA:C	donor_gain	0.9800
19:51520257:T:C	acceptor_gain	0.9700
19:51529722:A:AC	donor_gain	0.9700
19:51529723:C:CC	donor_gain	0.9700
19:51530128:C:A	donor_gain	0.9700
19:51530878:C:T	acceptor_gain	0.9700
19:51531155:CTT:C	donor_loss	0.9700

AlphaMissense

2919 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:51531308:G:C	F93L	0.989
19:51531308:G:T	F93L	0.989
19:51531310:A:G	F93L	0.989
19:51531309:A:C	F93C	0.966
19:51530841:C:A	W182C	0.960
19:51530841:C:G	W182C	0.960
19:51531309:A:G	F93S	0.960
19:51531383:G:C	F68L	0.959
19:51531383:G:T	F68L	0.959
19:51531385:A:G	F68L	0.959
19:51531264:A:G	I108T	0.948
19:51529880:A:G	W286R	0.944
19:51529880:A:T	W286R	0.944
19:51529915:C:G	C274S	0.944
19:51529916:A:T	C274S	0.944
19:51530843:A:G	W182R	0.944
19:51530843:A:T	W182R	0.944
19:51530744:A:G	C215R	0.943
19:51529878:C:A	W286C	0.942
19:51529878:C:G	W286C	0.942
19:51530891:A:G	C166R	0.942
19:51531243:T:G	D115A	0.941
19:51530847:G:C	F180L	0.935
19:51530847:G:T	F180L	0.935
19:51530849:A:G	F180L	0.935
19:51530890:C:G	C166S	0.935
19:51530891:A:T	C166S	0.935
19:51529780:C:G	C319S	0.931
19:51529781:A:T	C319S	0.931
19:51529875:G:C	F287L	0.930

dbSNP variants (sampled 300 via entrez): RS1000167340 (19:51518955 T>A), RS1000175149 (19:51521605 G>A), RS1000191172 (19:51525498 GC>G), RS1000472378 (19:51532380 A>G,T), RS1000473272 (19:51519076 A>T), RS1000521297 (19:51532746 A>G), RS1000807731 (19:51526668 T>C), RS1001295507 (19:51522718 G>T), RS1001498503 (19:51517331 T>C), RS1001614920 (19:51519403 T>C), RS1001732329 (19:51528551 A>G), RS1001896938 (19:51530323 T>C), RS1001979854 (19:51519123 G>A), RS1002616092 (19:51520786 G>T), RS1002812467 (19:51529560 G>A)

Disease associations

OMIM: gene MIM:604405 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003114_3	Carotid intima media thickness	4.000000e-09
GCST006585_27	Blood protein levels	1.000000e-114

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD33-related SIGLECs

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression	2
titanium dioxide	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
sulforaphane	decreases expression	1
butyraldehyde	decreases expression	1
pentanal	decreases expression	1
monomethylpropion	increases expression	1
(+)-JQ1 compound	decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	increases methylation	1
Allergens	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Diethylhexyl Phthalate	increases expression	1
Folic Acid	decreases expression	1
Silver	increases expression	1
Tetradecanoylphorbol Acetate	affects cotreatment, affects expression	1
Valproic Acid	increases methylation	1
Zinc	affects cotreatment, affects expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer